Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9988)
All Articles published online
|
Publishing Process of This Article
|
Aug 7, 2014 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of |
|---|---|
| URL: | https://www.wjgnet.com/2150-5330/full/v20/i29/9898.htm |
| Number | Citing Articles |
| 1 |
Nazlı Arslan, Özlem Yılmaz, Ebru Demiray-Gürbüz. Importance of antimicrobial susceptibility testing for the management of eradication in <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2017; 23(16): 2854-2869 doi: 10.3748/wjg.v23.i16.2854
|
| 2 |
Logan T. Roberts, Peter P. Issa, Evan S. Sinnathamby, Mallory Granier, Holly Mayeux, Treniece N. Eubanks, Kevin Malone, Shahab Ahmadzadeh, Elyse M. Cornett, Sahar Shekoohi, Alan D. Kaye. Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice. Life 2022; 12(12): 2038 doi: 10.3390/life12122038
|
| 3 |
Amirarsalan Serajian. PCR-RFLP Detection of Point Mutations in 23sr RNA Gene Responsible for Clarithromycin Resistance in Helicobacter pylori Isolates of Ahvaz, Iran. International Journal of Molecular Biology 2017; 2(5) doi: 10.15406/ijmboa.2017.02.00038
|
| 4 |
Sotirios D. Georgopoulos, Elias Xirouchakis, Christos Liatsos, Pericles Apostolopoulos, Panagiotis Kasapidis, Beatriz Martinez-Gonzalez, Fotini Laoudi, Maria Stoupaki, Georgios Axiaris, Dionysios Sgouras, Andreas Mentis, Spyridon Michopoulos. Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for Helicobacter pylori Eradication in High Clarithromycin Resistance Areas. Antibiotics 2024; 13(3): 280 doi: 10.3390/antibiotics13030280
|
| 5 |
Dana Binyamin, Nina Pastukh, Avi On, Maya Paritsky, Avi Peretz. Phenotypic and genotypic correlation as expressed in Helicobacter pylori resistance to clarithromycin and fluoroquinolones. Gut Pathogens 2017; 9(1) doi: 10.1186/s13099-017-0198-5
|
| 6 |
Vasiliki K. Pachi, Eleni V. Mikropoulou, Petros Gkiouvetidis, Konstantinos Siafakas, Aikaterini Argyropoulou, Apostolis Angelis, Sofia Mitakou, Maria Halabalaki. Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): A review. Journal of Ethnopharmacology 2020; 254: 112485 doi: 10.1016/j.jep.2019.112485
|
| 7 |
Periklis Apostolopoulos, Konstantinos Ekmektzoglou, Sotirios Georgopoulos, Eleni Chounta, Antonia Theofanopoulou, Chrisostomos Kalantzis, Erasmia Vlachou, Panagiotis Tsibouris, Georgios Alexandrakis. 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology 2020; 54(6): 522 doi: 10.1097/MCG.0000000000001328
|
| 8 |
Adrian G. McNicholl, A. Salvador Pena, Javier P. Gisbert. Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy. European Journal of Internal Medicine 2016; 33: 1 doi: 10.1016/j.ejim.2016.06.002
|
| 9 |
Kh. R. Aslanova. SOME RESULTS AND PROSPECTS OF THE STUDY OF HELICOBACTER PYLORI INFECTION. Bulletin of Problems Biology and Medicine 2019; 1(2): 111 doi: 10.29254/2077-4214-2019-1-2-149-111-114
|
| 10 |
Wei-Chen Tai, Chih-Ming Liang, Chen-Hsiang Lee, Chien-Hua Chiu, Ming-Luen Hu, Lung-Sheng Lu, Yuan-Hung Kuo, Chung-Mou Kuo, Yi-Hao Yen, Chung-Huang Kuo, Shue-Shian Chiou, Keng-Liang Wu, Yi-Chun Chiu, Tsung-Hui Hu, Seng-Kee Chuah. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-LineHelicobacter pyloriEradication. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/623732
|
| 11 |
Shun-Hsien Chang, Pei-Ling Hsieh, Guo-Jane Tsai. Chitosan Inhibits Helicobacter pylori Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells. Marine Drugs 2020; 18(11): 542 doi: 10.3390/md18110542
|
| 12 |
Enrico Celestino Nista, Antonio Pellegrino, Lucia Giuli, Marcello Candelli, Tommaso Schepis, Sara Sofia De Lucia, Veronica Ojetti, Francesco Franceschi, Antonio Gasbarrini. Clinical Implications of Helicobacter pylori Antibiotic Resistance in Italy: A Review of the Literature. Antibiotics 2022; 11(10): 1452 doi: 10.3390/antibiotics11101452
|
| 13 |
Alba A. Trespalacios, Emiko Rimbara, William Otero, Rita Reddy, David Y. Graham. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagnostic Microbiology and Infectious Disease 2015; 81(4): 251 doi: 10.1016/j.diagmicrobio.2014.12.003
|
| 14 |
You‐hua Wang, Zhi‐fa Lv, Yao Zhong, Dong‐sheng Liu, Shu‐ping Chen, Yong Xie. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter 2017; 22(1) doi: 10.1111/hel.12324
|
| 15 |
Sotirios Georgopoulos, Vasilios Papastergiou. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 2021; 22(6): 729 doi: 10.1080/14656566.2020.1845649
|
| 16 |
Zhi-Ning Ye, Harry Hua-Xiang Xia, Ran Zhang, Lan Li, Li-Hao Wu, Xu-Juan Liu, Wen-Rui Xie, Xing-Xiang He, Fa-Ming Zhang. The Efficacy of Washed Microbiota Transplantation on Helicobacter pylori Eradication: A Pilot Study. Gastroenterology Research and Practice 2020; 2020: 1 doi: 10.1155/2020/8825189
|
| 17 |
Sandra Salillas, Miriam Alías, Valérie Michel, Alejandro Mahía, Ainhoa Lucía, Liliana Rodrigues, Jessica Bueno, Juan José Galano-Frutos, Hilde De Reuse, Adrián Velázquez-Campoy, José Alberto Carrodeguas, Carlos Sostres, Javier Castillo, José Antonio Aínsa, María Dolores Díaz-de-Villegas, Ángel Lanas, Eliette Touati, Javier Sancho. Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice. Journal of Medicinal Chemistry 2019; 62(13): 6102 doi: 10.1021/acs.jmedchem.9b00355
|
| 18 |
Emma F. Jacquier, Marcel van de Wouw, Elena Nekrasov, Nikhat Contractor, Amira Kassis, Diana Marcu. Local and Systemic Effects of Bioactive Food Ingredients: Is There a Role for Functional Foods to Prime the Gut for Resilience?. Foods 2024; 13(5): 739 doi: 10.3390/foods13050739
|
| 19 |
Leila Manzouri, Farzaneh Zarei, Narjes Niazi, Moslem Sedaghattalab. Comparison of the Success Rate of Quadruple and Triple Antibiotic Therapy in Eradicating Helicobacter pylori Infection in Southwest of Iran: A Randomized Clinical Trial. International Journal of Infection 2017; 4(3) doi: 10.5812/iji.15610
|
| 20 |
Periklis Apostolopoulos, Ioannis Koumoutsos, Konstantinos Ekmektzoglou, Panagiotis Dogantzis, Erasmia Vlachou, Chrisostomos Kalantzis, Panagiotis Tsibouris, Georgios Alexandrakis. Concomitant versus sequential therapy for the treatment ofHelicobacter pyloriinfection: a Greek randomized prospective study. Scandinavian Journal of Gastroenterology 2016; 51(2): 145 doi: 10.3109/00365521.2015.1079646
|
| 21 |
Apostolis Papaefthymiou, Christos Liatsos, Sotirios D Georgopoulos, Pericles Apostolopoulos, Michael Doulberis, Nikolaos Kyriakos, Marios Giakoumis, Michael Papadomichelakis, Michail Galanopoulos, Panagiotis Katsinelos, Theodore Rokkas, Jannis Kountouras. Helicobacterpylori eradication regimens in an antibiotic high‐resistance European area: A cost‐effectiveness analysis. Helicobacter 2020; 25(1) doi: 10.1111/hel.12666
|
| 22 |
Nava Raj Sharma, Abhishesh Wagle, Manoj Bist, Bishal Panthi, Ritu Pokhrel Dahal, Rajesh Rokaya, Rayana Shrestha, Madalasa Pokhrel. Clarithromycin-induced acute liver injury in a patient with positive Helicobacter pylori: a case report and review of the literature. Annals of Medicine & Surgery 2023; 85(9): 4629 doi: 10.1097/MS9.0000000000001135
|
| 23 |
Nilanjana Das, Mangala Lakshmi Ragavan, Sanjeeb Kumar Mandal. Probiotics in the Prevention and Management of Human Diseases. 2022; : 281 doi: 10.1016/B978-0-12-823733-5.00001-5
|
| 24 |
Mohsen Karbalaei, Amin Talebi Bezmin Abadi, Masoud Keikha. Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis. BMC Infectious Diseases 2022; 22(1) doi: 10.1186/s12879-022-07546-5
|
| 25 |
Vanita Mulay, Dhanashri Satav, Austin Fernandez, Priyanka Pisalwar, Shadab Ahmed. Alternatives to Antibiotics. 2022; : 499 doi: 10.1007/978-981-19-1854-4_20
|
| 26 |
Ana Morilla Morilla, Marta E. Álvarez-Argüelles, Jose María Duque, Edisa Armesto, Henar Villar, Santiago Melón. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología (English Edition) 2019; 42(8): 476 doi: 10.1016/j.gastre.2019.05.003
|
| 27 |
Samuel Costa, João-Bruno Soares, Raquel Gonçalves. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1258 doi: 10.1097/MEG.0000000000000960
|
| 28 |
Lorena Elena Meliț, Cristina Oana Mărginean, Maria Oana Săsăran. The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics. Children 2022; 9(6): 795 doi: 10.3390/children9060795
|
| 29 |
Reka Borka Balas, Lorena Elena Meliț, Cristina Oana Mărginean. Current Worldwide Trends in Pediatric Helicobacter pylori Antimicrobial Resistance. Children 2023; 10(2): 403 doi: 10.3390/children10020403
|
| 30 |
Sotirios D Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Treatment ofHelicobacter Pyloriinfection: optimization strategies in a high resistance era. Expert Opinion on Pharmacotherapy 2015; 16(15): 2307 doi: 10.1517/14656566.2015.1084503
|
| 31 |
Han Chen, Yini Dang, Xiaoying Zhou, Bingtuan Liu, Shiyu Liu, Guoxin Zhang. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication. Medicine 2016; 95(7): e2750 doi: 10.1097/MD.0000000000002750
|
| 32 |
Ana Morilla Morilla, Marta E. Álvarez-Argüelles, Jose María Duque, Edisa Armesto, Henar Villar, Santiago Melón. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología 2019; 42(8): 476 doi: 10.1016/j.gastrohep.2019.05.002
|
| 33 |
Paola Cuomo, Marina Papaianni, Andrea Fulgione, Fabrizia Guerra, Rosanna Capparelli, Chiara Medaglia. An Innovative Approach to Control H. pylori-Induced Persistent Inflammation and Colonization. Microorganisms 2020; 8(8): 1214 doi: 10.3390/microorganisms8081214
|
| 34 |
Xin Yan Zhu, Fei Liu. Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy. Journal of Digestive Diseases 2017; 18(4): 195 doi: 10.1111/1751-2980.12466
|
| 35 |
Giuseppe Losurdo, Floriana Giorgio, Andrea Iannone, Mariabeatrice Principi, Michele Barone, Alfredo Di Leo, Enzo Ierardi. Role of concomitant therapy for <i>Helicobacter pylori</i> eradication: A technical note. World Journal of Gastroenterology 2016; 22(38): 8638-8640 doi: 10.3748/wjg.v22.i38.8638
|
| 36 |
Jia Jia, Chongwen Zhang, Yaqi Liu, Yanqiang Huang, Yuefan Bai, Xudong Hang, Liping Zeng, Dongqing Zhu, Hongkai Bi. Armeniaspirol A: a novel anti‐Helicobacter pylori agent. Microbial Biotechnology 2022; 15(2): 442 doi: 10.1111/1751-7915.13807
|
| 37 |
Yun Lu, Jing Pang, Genzhu Wang, Xinxin Hu, Xue Li, Guoqing Li, Xiukun Wang, Xinyi Yang, Congran Li, Xuefu You. Quantitative proteomics approach to investigate the antibacterial response of Helicobacter pylori to daphnetin, a traditional Chinese medicine monomer. RSC Advances 2021; 11(4): 2185 doi: 10.1039/D0RA06677J
|
| 38 |
Caio Constantini Rosa, Jessé Rodrigues de Moraes. Tratamento Das Infecções Por Helicobacter Pylori: Revisão De Ensaios Clínicos. Journal of Medical Residency Review 2022; 1(1): e021 doi: 10.37497/JMRReview.v1i1.21
|
| 39 |
Kamila Goderska, Sonia Agudo Pena, Teresa Alarcon. Helicobacter pylori treatment: antibiotics or probiotics. Applied Microbiology and Biotechnology 2018; 102(1): 1 doi: 10.1007/s00253-017-8535-7
|
| 40 |
Ye Zhou, Tingzan Li, Liaqat Ali. Effects of Quadruple Therapy Combined with Probiotics on Helicobacter Pylori-Related Peptic Ulcer. Computational and Mathematical Methods in Medicine 2022; 2022: 1 doi: 10.1155/2022/1221190
|
| 41 |
Furui Zhang, Linhan Ni, Zhen Zhang, Xuegang Luo, Xuequan Wang, Wenmiao Zhou, Jiale Chen, Jing Liu, Yuliang Qu, Kunmei Liu, Le Guo. Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection. Microbial Cell Factories 2024; 23(1) doi: 10.1186/s12934-024-02321-4
|
| 42 |
Jonathon P Schubert, Jessica Gehlert, Christopher K Rayner, Ian C Roberts‐Thomson, Sam Costello, Arduino A Mangoni, Robert V Bryant. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2021; 36(6): 1450 doi: 10.1111/jgh.15352
|
| 43 |
Javier P. Gisbert. Empirical or susceptibility-guided treatment forHelicobacter pyloriinfection? A comprehensive review. Therapeutic Advances in Gastroenterology 2020; 13: 175628482096873 doi: 10.1177/1756284820968736
|
| 44 |
Mansour Amin, Ali Akbar Shayesteh, Amirarsalan Serajian, Hamed Goodarzi. Assessment of Metronidazole and Clarithromycin Resistance Among Helicobacter pylori Isolates of Ahvaz (Southwest of Iran) During 2015 - 2016 by Phenotypic and Molecular Methods. Jundishapur Journal of Microbiology 2019; (In Press) doi: 10.5812/jjm.80156
|
| 45 |
Zhi-Qiang Song, Li-Ya Zhou. Hybrid, sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication: A systematic review and meta-analysis. World Journal of Gastroenterology 2016; 22(19): 4766-4775 doi: 10.3748/wjg.v22.i19.4766
|
| 46 |
Qian Hu, Ze Peng, Lingli Li, Xin Zou, Lijun Xu, Jing Gong, Ping Yi. The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Pharmacology 2020; 10 doi: 10.3389/fphar.2019.01694
|
| 47 |
Muhammad Miftahussurur, Pradeep Krishna Shrestha, Phawinee Subsomwong, Rabi Prakash Sharma, Yoshio Yamaoka. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiology 2016; 16(1) doi: 10.1186/s12866-016-0873-6
|
| 48 |
Sohaib Khan, Mohamed Sharaf, Ishfaq Ahmed, Tehsin Ullah Khan, Samah Shabana, Muhammad Arif, Syed Shabi Ul Hassan Kazmi, Chenguang Liu. Potential utility of nano-based treatment approaches to address the risk ofHelicobacter pylori. Expert Review of Anti-infective Therapy 2022; 20(3): 407 doi: 10.1080/14787210.2022.1990041
|
| 49 |
Lyudmila Boyanova, Ivailo Evstatiev, Daniel Yordanov, Rumyana Markovska, Ivan Mitov. Three unsuccessful treatments of Helicobacter pylori infection by a highly virulent strain with quadruple antibiotic resistance. Folia Microbiologica 2016; 61(4): 307 doi: 10.1007/s12223-015-0439-2
|
| 50 |
K. Ghazvini, M. Keikha. Can Curcumin be used as a therapeutic agent to eradicate Helicobacter pylori infection? Evidence from human clinical trials. Le Pharmacien Hospitalier et Clinicien 2021; 56(1): 93 doi: 10.1016/j.phclin.2020.09.006
|
| 51 |
Judit Alarcón-Millán, Gloria Fernández-Tilapa, Enoc Mariano Cortés-Malagón, Carlos Alberto Castañón-Sánchez, José De Sampedro-Reyes, Iván Cruz-del Carmen, Reyes Betancourt-Linares, Adolfo Román-Román. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis. Infection, Genetics and Evolution 2016; 44: 190 doi: 10.1016/j.meegid.2016.06.044
|
| 52 |
Ahmet Yozgat, Benan Kasapoglu, Selim Demirci, Fevzi Coskun Sokmen. Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter Pylori in Turkey. Revista Española de Enfermedades Digestivas 2020; doi: 10.17235/reed.2020.7261/2020
|
| 53 |
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opinion on Pharmacotherapy 2022; 23(1): 63 doi: 10.1080/14656566.2021.1959914
|
| 54 |
Kiarash Ghazvini, Hossein Kamali, Hadi Farsiani, Masoud Yousefi, Masoud Keikha. Sustain-release lipid-liquid crystal formulations of pexiganan against Helicobacter pylori infection: in vitro evaluation in C57BL/6 mice. BMC Pharmacology and Toxicology 2024; 25(1) doi: 10.1186/s40360-024-00731-z
|
| 55 |
J. Benavides, P. Barrias, N. Piro, A. Arenas, A. Orrego, E. Pino, L. Villegas, E. Dorta, A. Aspée, C. López-Alarcón. Reaction of tetracycline with biologically relevant chloramines. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2017; 178: 171 doi: 10.1016/j.saa.2017.02.001
|
| 56 |
GHALIA KHODER, ASMA A. AL-MENHALI, FARAH AL-YASSIR, SHERIF M. KARAM. Potential role of probiotics in the management of gastric ulcer. Experimental and Therapeutic Medicine 2016; 12(1): 3 doi: 10.3892/etm.2016.3293
|
| 57 |
Muhammad Miftahussurur, Yoshio Yamaoka. Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective. Molecules 2015; 20(4): 6068 doi: 10.3390/molecules20046068
|
| 58 |
Omero Alessandro Paoluzi, Giovanna Del Vecchio Blanco, Emanuela Visconti, Manuela Coppola, Carla Fontana, Marco Favaro, Francesco Pallone. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for <italic>Helicobacter pylori</italic> eradication in Italy. World Journal of Gastroenterology 2015; 21(21): 6698-6705 doi: 10.3748/wjg.v21.i21.6698
|
| 59 |
Christos Liatsos, Apostolis Papaefthymiou, Nikolaos Kyriakos, Marios Giakoumis, Jannis Kountouras, Michail Galanopoulos, Periklis Apostolopoulos, Sotirios D. Georgopoulos, Christos Mavrogiannis, Aristomenis K. Exadaktylos, David Shiva Srivastava, Theodore Rokkas, Michael Doulberis. Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?. Medicina 2020; 56(3): 133 doi: 10.3390/medicina56030133
|
| 60 |
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
|
| 61 |
Valentina Iannuccelli, Eleonora Maretti, Monia Montorsi, Cecilia Rustichelli, Francesca Sacchetti, Eliana Leo. Gastroretentive montmorillonite-tetracycline nanoclay for the treatment of Helicobacter pylori infection. International Journal of Pharmaceutics 2015; 493(1-2): 295 doi: 10.1016/j.ijpharm.2015.06.049
|
| 62 |
Teresa Alarcón, Pedro Urruzuno, Maria Josefa Martínez, Diego Domingo, Laura Llorca, Ana Correa, Manuel López-Brea. Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades infecciosas y microbiologia clinica (English ed.) 2017; 35(5): 278 doi: 10.1016/j.eimce.2017.03.018
|
| 63 |
Muhammad Miftahussurur, Yoshio Yamaoka. Helicobacter pylori Research. 2016; : 519 doi: 10.1007/978-4-431-55936-8_23
|
| 64 |
Ran Han, Hong Lu, Ming-Wan Jiang, Ke-Wen Tan, Zhong Peng, Jia-Li Hu, Dian-Chun Fang, Chun-Hui Lan, Xiao-Ling Wu. Multicenter Study of Antibiotic Resistance Profile ofH. pyloriand Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/8547686
|
| 65 |
Amin Talebi Bezmin Abadi. Vaccine against <i>Helicobacter pylori</i>: Inevitable approach. World Journal of Gastroenterology 2016; 22(11): 3150-3157 doi: 10.3748/wjg.v22.i11.3150
|
| 66 |
M. Xia, H. Chen, S. Liu.
The synergy of resveratrol and alcohol against
Helicobacter pylori
and underlying anti‐
Helicobacter pylori
mechanism of resveratrol
. Journal of Applied Microbiology 2020; 128(4): 1179 doi: 10.1111/jam.14531
|
| 67 |
Rebecca Marrero Rolon, Scott A. Cunningham, Jayawant N. Mandrekar, Erin T. Polo, Robin Patel, Erin McElvania. Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. Journal of Clinical Microbiology 2021; 59(5) doi: 10.1128/JCM.03040-20
|
| 68 |
Teresa Alarcón, Pedro Urruzuno, Maria Josefa Martínez, Diego Domingo, Laura Llorca, Ana Correa, Manuel López-Brea. Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades Infecciosas y Microbiología Clínica 2017; 35(5): 278 doi: 10.1016/j.eimc.2016.02.010
|
| 69 |
Meltem Ayaş, Yeşim Gürol. Antibiotic Resistance of Helicobacter pylori in Turkey: A Systematic Review and Meta-Analysis. Microbial Drug Resistance 2023; 29(3): 96 doi: 10.1089/mdr.2022.0146
|
| 70 |
Maria Teresa Mascellino, Massimiliano De Angelis, Dania Al Ismail, Alessandra Oliva. Helicobacter pylori - From First Isolation to 2021. 2021; doi: 10.5772/intechopen.97026
|
| 71 |
Ahmed Morad Asaad, Gasser El-Azab, Eman Abdelsameea, Osama Elbahr, Ahmed Kamal, Mohamed Abdel-Samiee, Ahmed Abdelfattah, Heba Abdallah, Doha Maher, Ahmed El-Refaie, Samar Ebrahim Ghanem, Shamshul Ansari, Samah Mohammed Awad. Susceptibility patterns and virulence genotypes of <i>Helicobacter pylori</i> affecting eradication therapy outcomes among Egyptian patients with gastroduodenal diseases. World Journal of Gastroenterology 2023; 29(19): 2950-2960 doi: 10.3748/wjg.v29.i19.2950
|
| 72 |
Jed W. Fahey, Katherine K. Stephenson, Alison J. Wallace. Dietary amelioration of Helicobacter infection. Nutrition Research 2015; 35(6): 461 doi: 10.1016/j.nutres.2015.03.001
|